254 related articles for article (PubMed ID: 30834999)
1. Novel Imaging in Detection of Metastatic Prostate Cancer.
Smith CP; Laucis A; Harmon S; Mena E; Lindenberg L; Choyke PL; Turkbey B
Curr Oncol Rep; 2019 Mar; 21(4):31. PubMed ID: 30834999
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
4. The use of PET/CT in prostate cancer.
Li R; Ravizzini GC; Gorin MA; Maurer T; Eiber M; Cooperberg MR; Alemozzaffar M; Tollefson MK; Delacroix SE; Chapin BF
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):4-21. PubMed ID: 29230009
[TBL] [Abstract][Full Text] [Related]
5.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography (PET) radiotracers for prostate cancer imaging.
Walker SM; Lim I; Lindenberg L; Mena E; Choyke PL; Turkbey B
Abdom Radiol (NY); 2020 Jul; 45(7):2165-2175. PubMed ID: 32047993
[TBL] [Abstract][Full Text] [Related]
7.
Selnæs KM; Krüger-Stokke B; Elschot M; Willoch F; Størkersen Ø; Sandsmark E; Moestue SA; Tessem MB; Halvorsen D; Kjøbli E; Angelsen A; Langørgen S; Bertilsson H; Bathen TF
Eur Radiol; 2018 Aug; 28(8):3151-3159. PubMed ID: 29294158
[TBL] [Abstract][Full Text] [Related]
8. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
[TBL] [Abstract][Full Text] [Related]
9. The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis.
Sathianathen NJ; Butaney M; Konety BR
World J Urol; 2019 Jul; 37(7):1239-1249. PubMed ID: 30003375
[TBL] [Abstract][Full Text] [Related]
10. Rapidly changing landscape of PET/CT imaging in prostate cancer.
Morigi JJ; Fanti S; Murphy D; Hofman MS
Curr Opin Urol; 2016 Sep; 26(5):493-500. PubMed ID: 27467137
[TBL] [Abstract][Full Text] [Related]
11. New aspects of molecular imaging in prostate cancer.
Ceci F; Castellucci P; Cerci JJ; Fanti S
Methods; 2017 Nov; 130():36-41. PubMed ID: 28711565
[TBL] [Abstract][Full Text] [Related]
12. Performance of
Bailey J; Piert M
Curr Urol Rep; 2017 Sep; 18(11):84. PubMed ID: 28889366
[TBL] [Abstract][Full Text] [Related]
13.
Malaspina S; De Giorgi U; Kemppainen J; Del Sole A; Paganelli G
Radiol Med; 2018 Dec; 123(12):952-965. PubMed ID: 30116970
[TBL] [Abstract][Full Text] [Related]
14. [The role of molecular imaging (PET-CT) in the diagnostic and treatment pf prostate cancer].
Mirzaei S; Knoll P; Zandieh S
Wien Med Wochenschr; 2019 Feb; 169(1-2):12-14. PubMed ID: 30349972
[TBL] [Abstract][Full Text] [Related]
15. Prostate imaging: Contribution of PET PSMA and MRI.
Abecassis JP; Ghazzar N; Peyromaure M; Giraud P
Cancer Radiother; 2020 Aug; 24(5):423-428. PubMed ID: 32620459
[TBL] [Abstract][Full Text] [Related]
16.
Kanoun S; Walker P; Vrigneaud JM; Depardon E; Barbier V; Humbert O; Moulin M; Créhange G; Cormier L; Loffroy R; Brunotte F; Cochet A
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):986-994. PubMed ID: 28333020
[TBL] [Abstract][Full Text] [Related]
17. Integrated
Lütje S; Cohnen J; Gomez B; Grüneisen J; Sawicki L; Rübben H; Bockisch A; Umutlu L; Pöppel TD; Wetter A
Nuklearmedizin; 2017 Jun; 56(3):73-81. PubMed ID: 28401244
[TBL] [Abstract][Full Text] [Related]
18. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
[TBL] [Abstract][Full Text] [Related]
19. Comparison Between
Cantiello F; Crocerossa F; Russo GI; Gangemi V; Ferro M; Vartolomei MD; Lucarelli G; Mirabelli M; Scafuro C; Ucciero G; De Cobelli O; Morgia G; Damiano R; Cascini GL
Clin Genitourin Cancer; 2018 Oct; 16(5):385-391. PubMed ID: 29937067
[TBL] [Abstract][Full Text] [Related]
20. The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer.
Koschel S; Murphy DG; Hofman MS; Wong LM
Curr Opin Urol; 2019 Nov; 29(6):569-577. PubMed ID: 31567440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
